Investment
Features
FeesSafety
Academy
More
Pluang+

Silver Elephant Mining ups private placement to raise CAD 882K for working capital.

Company Fundamentals
29 Sep 2026
Newsfile Corp
View Source
Neutral
Silver Elephant Mining ups private placement to raise CAD 882K for working capital.

Silver Elephant Mining Corp. has increased its non-brokered private placement to 7.35 million units at CAD 0.12 each, aiming to raise up to CAD 882,000. Each unit includes one common share and one warrant to buy an additional share at CAD 0.16 within three years. The funds raised will primarily support general working capital needs. The company expects to complete the placement by October 9, 2026, pending Toronto Stock Exchange approval.

Silver Elephant's private placement news provides context for readers interested in basic materials. For readers following this sector, here is Pluang's market snapshot as of Sep 30, 2026 02:51 WIB: Among 38 priced US basic materials stocks, 17 rose and 21 fell. Notably, ICL gained 3.19% at USD 5.18 with a typical hold time of 56 days, contrasting with NUE and MT, which fell 3.46% and 2.81% to USD 236.04 and USD 67.89 respectively, with NUE held typically for 77 days and MT for 35 days on Pluang.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
55 minutes ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
2 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
3 hours ago
ACRES Commercial Realty approves $5M more for share buyback program

ACRES Commercial Realty approves $5M more for share buyback program

ACRES Commercial Realty Corp. announced its board approved an additional $5 million for its existing share repurchase program. The company plans to buy back shares through various methods depending on market conditions but has not set a specific time...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App